Quarterly ResultAug 6, 2026, 04:24 PM
IN8bio Faces Going Concern Doubt; Cash Drops to $17.96M
AI Summary
IN8bio, Inc. reported a net loss of $9.87 million for the six months ended June 30, 2026, with cash and restricted cash decreasing to $18.13 million. The company explicitly stated substantial doubt about its ability to continue as a going concern, as existing cash is not expected to fund operations for the next 12 months. Management is implementing cash preservation measures and seeking additional capital through equity/debt offerings and collaborations, including potential proceeds of up to $29.1 million from warrant exercises.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $(9.87) million.
- Cash and restricted cash decreased to $18.13 million as of June 30, 2026.
- Company expressed substantial doubt about its ability to continue as a going concern.
- Net cash used in operating activities was $(8.69) million for the six months.
- Accumulated deficit reached $(150.97) million as of June 30, 2026.
- Potential additional proceeds of up to $29.1 million from warrant exercises.
- A one-for-thirty reverse stock split was effected in June 2025.
Price Impact
More from INAB